Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs ZVRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: CAPR 1 – 5 ZVRA Matrix Metrics: CAPR 0 – 10 ZVRA

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ZVRA carries 49.3/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin).

  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs ZVRA
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.31
+2.53% 1D
Market Cap $664.1M
TTM Revenue $148M
Forward P/E 9.3x
Beta / 30D Vol 1.18β · 95% Vol
Unified Composite Score
49.3 / 100 HOLD
Tech 36.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 40
RSI-14: 39.6 · SMA20: $10.53 · SMA50: $10.93

6-Pillar Scorecard Institutional Category Breakdown (CAPR 1 – 5 ZVRA)

Columns: Metric · CAPR · ZVRA
1. Valuation Multiples ZVRA
Forward P/E 78.7x 9.3x
Trailing P/E 78.7x 9.7x
PEG Ratio 0.38x 10.67x
EV / Revenue 57.8x 3.7x
2. Growth & Scale ZVRA
Revenue Growth (YoY) -7.9% +44.9%
Earnings Growth (YoY) +0.0% -88.4%
TTM Revenue (USD) $11M $148M
Market Cap $595.4M $664.1M
3. Profitability & Quality ZVRA
Gross Margin N/A 95.4%
Operating Margin 0.0% 31.5%
Net Profit Margin 0.0% 52.8%
Return on Equity (ROE) -100.5% 41.9%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) -$146M $38M
Cash Flow Margin N/A 25.9%
Net Cash / Leverage $48M Net Debt (0.44x D/E) $121M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 637.1% (89th %ile) 71.7% (14th %ile)
Put/Call OI Skew 1.57x (Put-Skewed) 1.62x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity N/A 63.9% of Rev ($94M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (0) vs ZVRA (10)
Institutional Metric CAPR ZVRA Criterion Row Edge
Market Capitalization
Scale
$595.4M $664.1M Larger Scale ZVRA
Trailing P/E Ratio
Valuation
78.7x 9.7x Lower Multiple ZVRA
Forward P/E Ratio
Valuation
78.7x 9.3x Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
-7.9% +44.9% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
0.0% 31.5% Higher Margin ZVRA
Net Profit Margin
Profitability
0.0% 52.8% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
-100.5% 41.9% Higher ROE ZVRA
52-Week Range Position
Momentum
15% ($3–$40) 18% ($8–$15) Stronger Trend ZVRA
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 1.18β · 95% Vol Lower Realized Risk ZVRA
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 49.3 / 100 (HOLD) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
$11M $148M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 95.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev 10.67x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) $38M ($121M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +32.57 pp
CAPR: +26.23% · ZVRA: -6.34%
3M Horizon CAPR +39.16 pp
CAPR: +19.63% · ZVRA: -19.53%
6M Horizon ZVRA +55.14 pp
CAPR: -70.58% · ZVRA: -15.44%
1Y Horizon CAPR +45.92 pp
CAPR: +46.79% · ZVRA: +0.87%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAPR Revenue ZVRA Revenue CAPR Op. Margin ZVRA Op. Margin Margin Leader
FY2018 $0M N/A -917.0% N/A CAPR
FY2019 $0M $10M -769.5% -158.4% ZVRA
FY2020 $0M $10M -4412.6% -42.2% ZVRA
FY2021 $0M $30M -8549.9% 27.0% ZVRA
FY2022 $0M $10M -1163.9% -418.9% ZVRA
FY2023 $30M $30M -95.6% -180.6% CAPR
FY2024 $20M $20M -191.1% -368.5% CAPR
FY2025 N/A $110M N/A -59.1% ZVRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 71.7%
IV Percentile 14th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $664.1M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs ZVRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ZVRA carries 49.3/100 (HOLD) at $9.31 (9.3x Forward P/E, 31.5% operating margin). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ZVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with ZVRA at +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAPR cumulative revenue shifted -33.3% while ZVRA shifted +1000.0%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus 63.9% of Rev ($94M) (0 disclosures) for ZVRA.

ZVRA screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas ZVRA trades at 9.3x Forward P/E, 9.7x Trailing P/E, 10.67x PEG, and 3.7x EV/Revenue (25.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus ZVRA (41.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, ZVRA carries 71.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.